Immunotherapy for cancer in the central nervous system: Current and future directions

David C. Binder*, Andrew A. Davis, Derek A. Wainwright

*Corresponding author for this work

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and still remains incurable. Although immunotherapeutic vaccination against GBM has demonstrated immune-stimulating activity with some promising survival benefits, tumor relapse is common, highlighting the need for additional and/or combinatorial approaches. Recently, antibodies targeting immune checkpoints were demonstrated to generate impressive clinical responses against advanced melanoma and other malignancies, in addition to showing potential for enhancing vaccination and radiotherapy (RT). Here, we summarize the current knowledge of central nervous system (CNS) immunosuppression, evaluate past and current immunotherapeutic trials and discuss promising future immunotherapeutic directions to treat CNS-localized malignancies.

Original languageEnglish (US)
JournalOncoImmunology
Volume5
Issue number2
DOIs
StatePublished - Feb 1 2016

Keywords

  • Brain metastases
  • IDO
  • T cell therapy
  • glioblastoma
  • glioma
  • vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Immunotherapy for cancer in the central nervous system: Current and future directions'. Together they form a unique fingerprint.

  • Cite this